RARE ULTRAGENYX PHARMACEUTICAL INC Product Launches 8-K Filing 2023 - Phase 2 Orbit study data announcement Ultragenyx Pharmaceutical Inc. announced data from the Phase 2 portion of the Orbit study, showing positive results in bone production in OI-affected patients.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC